HC Wainwright Has Strong Forecast for DTIL FY2030 Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Equities research analysts at HC Wainwright increased their FY2030 earnings per share (EPS) estimates for Precision BioSciences in a research report issued to clients and investors on Monday, August 3rd. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $1.09 per share for the year, up from their prior forecast of $1.08. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is ($2.21) per share.

DTIL has been the subject of a number of other research reports. Weiss Ratings raised shares of Precision BioSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. JonesTrading reiterated a “buy” rating and issued a $30.00 target price on shares of Precision BioSciences in a report on Friday, April 17th. Finally, Oppenheimer initiated coverage on shares of Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.25.

Precision BioSciences Stock Performance

NASDAQ DTIL opened at $7.06 on Tuesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 14.02 and a current ratio of 14.02. The stock’s fifty day moving average is $7.35 and its two-hundred day moving average is $6.25. The firm has a market capitalization of $182.15 million, a P/E ratio of -1.92 and a beta of 1.27. Precision BioSciences has a fifty-two week low of $3.53 and a fifty-two week high of $9.62.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.09). The company had revenue of $10.84 million for the quarter, compared to analysts’ expectations of $4.05 million. Precision BioSciences had a negative return on equity of 85.37% and a negative net margin of 96.73%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. HBK Sorce Advisory LLC acquired a new stake in Precision BioSciences in the 4th quarter valued at about $38,000. Engineers Gate Manager LP acquired a new stake in Precision BioSciences in the fourth quarter valued at approximately $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences in the fourth quarter worth approximately $52,000. Miller Financial Services LLC grew its holdings in Precision BioSciences by 50.0% during the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Precision BioSciences in the 3rd quarter valued at approximately $84,000. 37.99% of the stock is owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.